Market Overview:
The global lung cancer liquid biopsy market is expected to grow at a CAGR of 16.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of lung cancer, technological advancements in the field of liquid biopsy, and increasing demand for early diagnosis and treatment of lung cancer. Based on type, the global market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes and RNA, and others. The ctDNA segment is expected to grow at the highest CAGR during the forecast period owing to its ability to detect mutations in tumors with high accuracy. Based on application, the market is segmented into clinics, hospitals, physicians' office laboratories, research institutes & academic centers, and others. The clinics segment accounted for the largest share of the global market in 2017 owing to rising demand for early diagnosis and treatment of lung cancer patients.
Product Definition:
Lung cancer liquid biopsy is the process of extracting cells or cell-free DNA from a tumor or other bodily fluid for analysis. Liquid biopsy has many advantages over traditional tissue biopsy, including the ability to detect mutations in circulating tumor DNA (ctDNA) that may not be present in the original tumor. This can help doctors determine whether a patient's cancer is responding to treatment.
CTCs:
CTCs are clinically important small non-carcinogenic cells that can be identified in the blood or urine using a technique called liquid biopsy. CTCs were first identified in 2007 and their number has been increasing at an exponential rate ever since. The current total number of known CTCs is around 1 million per milliliter, with a normal range of 10 to 100 per milliliter.
CtDNA:
Lung Cancer Liquid Biopsy (LLB) is a new and emerging technology that has been used in over 80% of lung cancer cases. It involves the testing of tissue or fluid samples for the presence of tumor-specific DNA (ctDNA). The test can detect early-stage lung cancer and helps rule out other conditions such as pneumonia, pulmonary embolism, and other non-cancerous diseases.
Application Insights:
The clinics segment dominated the global market in 2017. This can be attributed to rising incidence of lung cancer coupled with increasing awareness about liquid biopsies among patients. Liquid biopsy is considered an advanced diagnostic tool for lung cancer and its availability only at a few select hospitals and clinical centers has further driven growth.
Liquid biopsy is most commonly used in clinics as it offers benefits such as minimally invasive procedure, real-time results, and easy detection of tumor-specific biomarkers/molecules that are released during the treatment process. These factors have led to increased adoption of liquid biopsy for early diagnosis across various settings including private practices, hospital laboratories, research institutes and pharmaceutical companies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Quidel Corporation; downstream processing and analysis of liquid biopsy results by these companies, and high adoption rate for novel technologies in this region. The U.S., which is at the forefront of innovation across all sectors, has also contributed significantly to this growth through development of liquid biopsy-based cancer screening tests based on messenger RNA (mRNA) analysis techniques that are now FDA-approved for use as a diagnostic test for lung cancer detection.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing government initiatives pertaining towards quality healthcare delivery system coupled with rising awareness about liquid biopsy testing methods among physicians & patients in this region especially after China launched its national program using these methodologies since 2015 followed by New Zealand and Australia shortly thereafter making it one of the first countries worldwide implementing Lung Cancer Liquid Biopsy Tests (LCDTs).
Growth Factors:
- Increasing incidence of lung cancer
- Rising demand for personalized medicine
- Growing popularity of liquid biopsy tests
- Advances in technology and instrumentation
- Proliferation of targeted therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Liquid Biopsy Market Research Report
By Type
CTCs, CtDNA, Exosomes And RNA, Others
By Application
Clinics, Hospitals, Physicians' Office Laboratories
By Companies
Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, Qiagen, Accuragen, Agena Bioscience, Bard1, Bgi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
147
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Liquid Biopsy Market Report Segments:
The global Lung Cancer Liquid Biopsy market is segmented on the basis of:
Types
CTCs, CtDNA, Exosomes And RNA, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinics, Hospitals, Physicians' Office Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocept
- Exosome Diagnostics
- F. Hoffmann-La Roche
- Qiagen
- Accuragen
- Agena Bioscience
- Bard1
- Bgi
Highlights of The Lung Cancer Liquid Biopsy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CTCs
- CtDNA
- Exosomes And RNA
- Others
- By Application:
- Clinics
- Hospitals
- Physicians' Office Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Liquid Biopsy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liquid biopsy is a minimally invasive diagnostic technique that uses a small amount of liquid to collect cells and tissue from the lungs for analysis. Lung cancer liquid biopsy can help doctors diagnose lung cancer early, when it is most treatable.
Some of the major companies in the lung cancer liquid biopsy market are Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, Qiagen, Accuragen, Agena Bioscience, Bard1, Bgi.
The lung cancer liquid biopsy market is expected to grow at a compound annual growth rate of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lung Cancer Liquid Biopsy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lung Cancer Liquid Biopsy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lung Cancer Liquid Biopsy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lung Cancer Liquid Biopsy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lung Cancer Liquid Biopsy Market Size & Forecast, 2018-2028
4.5.1 Lung Cancer Liquid Biopsy Market Size and Y-o-Y Growth
4.5.2 Lung Cancer Liquid Biopsy Market Absolute $ Opportunity
Chapter 5 Global Lung Cancer Liquid Biopsy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lung Cancer Liquid Biopsy Market Size Forecast by Type
5.2.1 CTCs
5.2.2 CtDNA
5.2.3 Exosomes And RNA
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lung Cancer Liquid Biopsy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lung Cancer Liquid Biopsy Market Size Forecast by Applications
6.2.1 Clinics
6.2.2 Hospitals
6.2.3 Physicians' Office Laboratories
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lung Cancer Liquid Biopsy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lung Cancer Liquid Biopsy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lung Cancer Liquid Biopsy Analysis and Forecast
9.1 Introduction
9.2 North America Lung Cancer Liquid Biopsy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lung Cancer Liquid Biopsy Market Size Forecast by Type
9.6.1 CTCs
9.6.2 CtDNA
9.6.3 Exosomes And RNA
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lung Cancer Liquid Biopsy Market Size Forecast by Applications
9.10.1 Clinics
9.10.2 Hospitals
9.10.3 Physicians' Office Laboratories
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lung Cancer Liquid Biopsy Analysis and Forecast
10.1 Introduction
10.2 Europe Lung Cancer Liquid Biopsy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lung Cancer Liquid Biopsy Market Size Forecast by Type
10.6.1 CTCs
10.6.2 CtDNA
10.6.3 Exosomes And RNA
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lung Cancer Liquid Biopsy Market Size Forecast by Applications
10.10.1 Clinics
10.10.2 Hospitals
10.10.3 Physicians' Office Laboratories
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lung Cancer Liquid Biopsy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lung Cancer Liquid Biopsy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lung Cancer Liquid Biopsy Market Size Forecast by Type
11.6.1 CTCs
11.6.2 CtDNA
11.6.3 Exosomes And RNA
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lung Cancer Liquid Biopsy Market Size Forecast by Applications
11.10.1 Clinics
11.10.2 Hospitals
11.10.3 Physicians' Office Laboratories
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lung Cancer Liquid Biopsy Analysis and Forecast
12.1 Introduction
12.2 Latin America Lung Cancer Liquid Biopsy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lung Cancer Liquid Biopsy Market Size Forecast by Type
12.6.1 CTCs
12.6.2 CtDNA
12.6.3 Exosomes And RNA
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lung Cancer Liquid Biopsy Market Size Forecast by Applications
12.10.1 Clinics
12.10.2 Hospitals
12.10.3 Physicians' Office Laboratories
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lung Cancer Liquid Biopsy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lung Cancer Liquid Biopsy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lung Cancer Liquid Biopsy Market Size Forecast by Type
13.6.1 CTCs
13.6.2 CtDNA
13.6.3 Exosomes And RNA
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lung Cancer Liquid Biopsy Market Size Forecast by Applications
13.10.1 Clinics
13.10.2 Hospitals
13.10.3 Physicians' Office Laboratories
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lung Cancer Liquid Biopsy Market: Competitive Dashboard
14.2 Global Lung Cancer Liquid Biopsy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biocept
14.3.2 Exosome Diagnostics
14.3.3 F. Hoffmann-La Roche
14.3.4 Qiagen
14.3.5 Accuragen
14.3.6 Agena Bioscience
14.3.7 Bard1
14.3.8 Bgi
